ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,393.80
0.85%
S&P ASX All Technology
3,840.60
-1.02%
Brent Oil
74.65
0.00%
US Dollar vs AUD
1.53846
0.06%
Bitcoin
98,803.16
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Eli Lilly and Co (LLY)

  7. Eli Lilly and Co (LLY) News

LLY

Eli Lilly (LLY)

Eli Lilly and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:LLY
DateTimeSourceHeadlineSymbolCompany
21/11/202408:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/11/202408:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
20/11/202421:00GlobeNewswire Inc.Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALSNYSE:LLYEli Lilly and Co
20/11/202408:49Edgar (US Regulatory)Form 8-K - Current reportNYSE:LLYEli Lilly and Co
20/11/202408:30PR Newswire (US)Lilly announces changes on board of directorsNYSE:LLYEli Lilly and Co
19/11/202406:52PR Newswire (US)Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested doseNYSE:LLYEli Lilly and Co
17/11/202402:00PR Newswire (US)Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesityNYSE:LLYEli Lilly and Co
15/11/202411:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NYSE:LLYEli Lilly and Co
14/11/202409:05PR Newswire (US)Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeksNYSE:LLYEli Lilly and Co
09/11/202408:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
06/11/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
06/11/202408:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
06/11/202408:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
06/11/202401:04PR Newswire (US)Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual MeetingNYSE:LLYEli Lilly and Co
02/11/202408:30PR Newswire (US)Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer SymposiumNYSE:LLYEli Lilly and Co
02/11/202407:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
31/10/202402:54Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:LLYEli Lilly and Co
30/10/202422:05Edgar (US Regulatory)Form 8-K - Current reportNYSE:LLYEli Lilly and Co
30/10/202421:45PR Newswire (US)Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New ProductsNYSE:LLYEli Lilly and Co
30/10/202421:37IH Market NewsUS Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge UpNYSE:LLYEli Lilly and Co
30/10/202403:15PR Newswire (US)Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b studyNYSE:LLYEli Lilly and Co
29/10/202402:31PR Newswire (US)Lilly declares fourth-quarter 2024 dividendNYSE:LLYEli Lilly and Co
 Showing the most relevant articles for your search:NYSE:LLY

Your Recent History

BIT
AZM
Azimut Hldg
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved